- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Simnotrelvir and ritonavir combo may shorten time to symptom resolution in patients with COVID-19: NEJM
China: A phase 2-3 trial revealed a shortened time to resolve symptoms among adult COVID-19 patients with early administration of simnotrelvir plus ritonavir without evident safety concerns. The findings were published online in the New England Journal of Medicine on January 18, 2024.
"In the trial of treatment for mild-to-moderate COVID-19, simnotrelvir plus ritonavir shortened the time to sustained symptom resolution by about 1.5 days among patients who received treatment within 3 days after symptom onset," the researchers reported.
Simnotrelvir imparted more benefits for the alleviation of respiratory symptoms than a placebo. Also, simnotrelvir was associated with an additional decrease in viral load until day 9. On day 5, the most pronounced antiviral effect occurred when the reduction in viral load in the simnotrelvir group was 1.51 log10 copies per millilitre higher than in the placebo group. Most adverse events were mild or moderate.
The ongoing coronavirus disease 2019 pandemic continues to inflict an important burden on healthcare systems and global health. The effect of the disease on high-risk groups can be lessened by vaccination but is less effective in preventing infections caused by emerging SARS-CoV-2 variants with strong immune evasion. There is a need for effective antiviral agents for treating SARS-CoV-2 infections.
Numerous small-molecule drugs (e.g., ensitrelvir5 and nirmatrelvir4) are available that target the SARS-CoV-2 3-chymotrypsin–like cysteine protease enzyme (3CLpro, also known as main protease [Mpro]). However, more drug options are needed to accelerate the resolution of symptoms among patients with mild-to-moderate COVID-19 because of the high costs of the drugs and inequity in their distribution.
Simnotrelvir is an oral 3-chymotrypsin–-like protease inhibitor that has been reported to have in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and potential efficacy in a phase 1B trial. Bin Cao, Central People's Hospital of Zhanjiang, Zhanjiang, China, and colleagues conducted a phase 2–3, double-blind, randomized, placebo-controlled trial to determine the safety and efficacy of simnotrelvir plus ritonavir in the treatment of adult patients with mild-to-moderate Covid-19.
1208 patients were enrolled at 35 sites in China; 603 were assigned to receive simnotrelvir, and 605 to placebo.
Based on the study, the researchers reported the following findings:
- Among patients in the modified intention-to-treat population who received the first dose of a trial drug or placebo within 72 hours after symptom onset, the time to sustained resolution of COVID-19 symptoms was significantly shorter in the simnotrelvir group than in the placebo group (180.1 hours versus 216.0 hours).
- On day 5, the decrease in viral load from baseline was greater in the simnotrelvir group than in the placebo group (mean difference [±SE], -1.51±0.14 log10 copies per millilitre).
- The incidence of adverse events during treatment was higher in the simnotrelvir group than in the placebo group (29.0% vs. 21.6%).
- Most adverse events were mild or moderate.
"The findings showed that early administration of simnotrelvir plus ritonavir was effective in shortening the time to symptom resolution among adult patients with COVID-19, without evident safety concerns," the researchers concluded.
Reference:
Cao B, Wang Y, Lu H, Huang C, Yang Y, Shang L, Chen Z, Jiang R, Liu Y, Lin L, Peng P, Wang F, Gong F, Hu H, Cheng C, Yao X, Ye X, Zhou H, Shen Y, Liu C, Wang C, Yi Z, Hu B, Xu J, Gu X, Shen J, Xu Y, Zhang L, Fan J, Tang R, Wang C. Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19. N Engl J Med. 2024 Jan 18;390(3):230-241. doi: 10.1056/NEJMoa2301425. PMID: 38231624.
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751